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The  synthetic  peptide  GK-1,  derived  from  Taenia  crassiceps,  enhances  the  protection  induced  by human
inﬂuenza  vaccine  in both  young  and  aged  mice.  Herein,  the  adjuvant  properties  of  GK-1 fused  to  the  pVIII
protein  of a  heat-inactivated  phagemid  vector  (FGK1)  when  co-administered  with  the  inﬂuenza  vaccine
were  assessed,  to evaluate  its feasibility  as  a low-cost  adjuvant.  In mice,  FGK1  signiﬁcantly  increased





intranasally  or subcutaneously  co-administered  with  inﬂuenza  vaccine.  Single-dose  pig co-immunization
with  FGK1  and  inﬂuenza  vaccine  induced  serum  levels  of IgG anti-inﬂuenza  antibodies  similar  to  those
elicited  by  a  two-dose  immunization  with  the inﬂuenza  vaccine  alone.  Preclinical  evaluation  of  FGK1  with
the  inﬂuenza  vaccine  is  currently  in progress,  in  order  to recommend  its use  for  veterinary  purposes.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 
accination
. Introduction
The limited efﬁciency of the response to inﬂuenza vaccine
ue to immunosenescence and seasonal viral differences has
een dealt with by different approaches [1]. Among them ﬁg-
res the immunopotentiation through the use of adjuvants [2].
he new knowledge on innate immunity brings renewed inter-
st in adjuvant development [20]. Adjuvants can act on at least
hree interdependent critical players involved in vaccine-induced
mmunity: antigen-presenting cells (APC), and T and B lymphocytes
3–5]. These are not-independent players, since APC activation
ould promote T and B activation, which in turn could modu-
ate APC activation and antigen presentation, and can respond in
 T–B interplay response mediated by numerous humoral factors
20].In a recent report it has been demonstrated that the 18-aa
eptide derived from Taenia crassiceps named GK-1 effectively acti-
ates dendritic antigen-presenting cells, enhancing the expression
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Open access under CC BY-Nof the major histocompatibility complex class II and co-stimulatory
molecules, and to promote the secretion of pro-inﬂammatory
cytokines (IFN and TNF). GK-1 also promotes the secretion of
the proinﬂammatory CCL2 [6], a chemokine that attracts mono-
cytes, NK cells, immature DCs, and activated T cells to the lymph
nodes draining the site of immunization [7]. These effects probably
underlie the capacity of GK-1 to enhance the protective immunity
induced by inﬂuenza vaccine [8].
On the other hand, the effectiveness of adjuvants and vaccines
can be improved by using an adequate delivery system for their
presentation. A proper delivery system could also extend the vac-
cine usefulness to different administration routes, i.e. intranasal,
intradermal, or even oral [9,10].
In this study, GK-1 was  recombinantly expressed in ﬁlamentous
bacteriophages for its delivery, to enhance the effectiveness of GK-1
as an adjuvant. These phages are widely employed as immunogenic
carriers for “phage-displayed” recombinant peptides [11]. They are
reported as effective delivery systems for expressing peptides in
multiple copies [12]. Peptide epitopes in the hybrid bacteriophages
were found to be strongly immunogenic against different infec-
tious diseases without the need of external adjuvants [13,14]. GK-1
was recombinantly bound to the pVIII protein, the major protein of
the capsid exposing N-terminal regions on the viral surface (FGK1).
Considering that inﬂuenza virus enters through mucosal surfaces,
the effectiveness of FGK1 was  evaluated when subcutaneously and
intranasally co-administered with the inactivated human vaccine.
C-SA license. 
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ince MF59 vaccine adjuvant has been licensed for human use to
mprove the inﬂuenza vaccine [15,16], the effectiveness of the latter
ersus FGK1 was also compared.
. Materials and methods
.1. Mice
BALB/cAnN female mice (7–8 week-old) originally obtained
rom Harlan (Mexico City) and bred in our animal facilities at the
nstituto de Investigaciones Biomédicas (IIBM) of the Universidad
acional Autónoma de México were employed. Aged female BALB/c
ice, 20 month-old, were obtained from Gador S.A. Laboratory
Buenos Aires, Argentina). All animals were housed and bred under
arrier conditions in the animal facilities at the IIBM in Mexico or at
he Ricardo Gutiérrez Children’s Hospital, Buenos Aires, Argentina.
ll animal studies have been approved by the IIBM Ethical Com-
ittee.
.2. Pigs
Forty 4-week-old cross-bred pigs (Landrace × Pietrain) were
urchased from the Centro de Ensen˜anza, Investigación y Exten-
ionismo en Producción Porcina (CEIEPP) of the Facultad de
edicina Veterinaria y Zoootecnia, UNAM. Pigs were free from
nfection with inﬂuenza virus (no clinical signs of respira-
ory disease were observed). Sows had been vaccinated against
nﬂuenza virus, and all piglets were screened for inﬂuenza anti-
odies, using hemagglutination inhibition (HI) test and enzyme-
inked immunosorbent assay (ELISA) prior to the start of the
tudy.
.3. Virus strains
Inﬂuenza virus H1N1: Inﬂuenza A virus (A/swine/New
ersey/11/1976) and Inﬂuenza A virus H3N2:
A/Swine/Minnesota/9088-2/98) were proliferated in the allan-
oic sac of chicken embryos following the procedure previously
escribed [17]. After culture, a hemagglutination titer of 1:64 and
:128 was obtained, respectively. For hemagglutination tests, the
irus was inactivated with UV light at a wavelength of 300 nm for
0 min  and subsequently by formaldehyde (ﬁnal concentration
.025%) for 72 h at 4 ◦C.
.4. Inﬂuenza vaccines
Mice were vaccinated with inactivated Fluzone®, FLUAD®
Mexico) or Istivac® (Argentina) inﬂuenza vaccine (IV) stocks,
ach containing three different strains: Fluzone® 2008/2009:
/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (strain derived:
/Brisbane/10/2007) (H3N2) and B/Florida/04/2006. FLUAD®:
/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (analogous strain
/Uruguay/716/2007, NYMC X-175C) and B/Florida/04/2006.
stivac®: 2008/2009: A/Solomon Islands/3/2006 (H1N1)-like virus
/Brisbane/10/2007 (H3N2)-like virus; strain B: B/Florida/4/2006-
ike virus. Each tube contained 45 g of hemagglutinins (HA) per
.5 ml,  which included 15 g of each strain.
Pigs were intramuscularly (IM) vaccinated with 2 ml  of a com-
ercial licensed porcine inﬂuenza vaccine (FluSure XP®, Pﬁzer
nimal Health, New York, USA, 2010) containing two  type-A ﬁeld
solates subtypes H1N1 and H3N2 of inactivated swine inﬂuenza
iruses grown on an established cell line. A sterile diluent con-
aining the oil-in-water adjuvant Amphigen is also included to
ehydrate the freeze-dried vaccine.ine 31 (2013) 4009– 4016
2.5. Construction of phage (PVIII)-GK-1
KETc7-derived peptide GK-1 (aa 69–85, GYYYPSDPNTFYAP-
PYSA) was expressed on the phage surface by cloning the
corresponding DNA fragments in phage/phagemid vectors as pre-
viously reported [18]. The recombinant phagemids FGK1 (fused
GK-1 to M13  cpVIII) were recovered and ampliﬁed by superin-
fection with M13KO7 helper phage (Invitrogen) from transformed
Escherichia coli TG-1 cells, as described previously [18].
2.6. Large-scale preparation and inactivation
M13  ﬁlamentous phage releases its progeny particles by a secre-
tory process without lysing the bacterial cell [14]. Thus, it is feasible
to recover the recombinant phagemid with low amounts of bacte-
rial products in culture supernatants at 1012 to 1014 particles per
ml after centrifugation at 10,000 rpm by 10 min. Afterwards, super-
natants were inactivated and sterilized in one step in an autoclave
during 30 min  at 15 lbs. Formaldehyde was added at 0.05% to the
heat-inactivated phage particles as a preservative.
2.7. Mouse immunization
Groups of ﬁve BALB/cAnN female mice received single subcuta-
neous (SC) or intranasal (IN) immunizations each with inactivated
Fluzone®, FLUAD® (Mexico) inﬂuenza vaccine (1.0 g per mouse)
with or without FGK1, or M13  or FGK1 alone (1 × 1012 particles).
Groups of ﬁve aged mice were intranasally immunized once with
the Istivac® (Argentina) inﬂuenza vaccine. All immunogens admin-
istered subcutaneously were included in 100 l of SSI. Intranasal
formulation (30 l/nostril) was  delivered using a pipette. To assess
the synergistic effects of MF59 adjuvant, mice were immunized
with either FLUAD® (1.0 g per mouse) alone or in combination
with FGK1. Serum and bronchoalveolar lavage ﬂuid (BALF) samples
were collected at different times after immunization: 21, 45, 75, and
120 days in young mice, and 21 and 45 days in aged mice, to mea-
sure antibody levels. Samples were stored at −20 ◦C. Euthanasia
was performed by cervical dislocation.
2.8. Testing mother anti-inﬂuenza antibodies
Prior to the study, groups of 4–5 pigs of 1, 2, 3, and 4 months
of age from the Veterinary School were bled and tested for the
presence of maternal anti-inﬂuenza A virus antibodies in serum
by ELISA and HIA. Piglets became immunized once low antibody
levels were detected by both techniques.
2.9. Pig immunization
Pigs purchased at 30 days old were randomly distributed into
four groups of 7 pigs each, and placed in separate isolation rooms
located at the farm of Jilotepec of the Facultad de Medicina Vet-
erinaria y Zoootecnia, UNAM, free from inﬂuenza virus. Pigs were
assigned to four different treatment groups as follows: Untreated
control group; vaccinated with inﬂuenza vaccine (two doses);
vaccinated with inﬂuenza vaccine (single dose) plus FGK1; and vac-
cinated with inﬂuenza vaccine (double dose) plus FGK1. Pigs were
fed ad libitum and allowed free access to water. Space allowance
was 6.3 square feet (0.58 m2) per pig. Blood samples were collected
from all pigs upon arrival to the research facility and tested for
antibodies by ELISA.
Piglets were vaccinated twice with inﬂuenza vaccine, 2.0 ml  per
pig, and with or without FGK1 (1 × 1013 phage per ml), 2.5 ml  per
pig, after verifying the reduction of maternal antibodies (one month
later). The ﬁrst dose was applied when piglets were 3 month-old,




















































BR. Segura-Velázquez et al.
igs at the start of the experiment and 30, 45, and 60 days after the
rst vaccination.
.10. Safety and tolerability of FGK1
Food and water was provided ad libitum. Following each immu-
ization pigs were examined two times daily and any abnormal
linical signs of illness or distress were registered. The rectal tem-
erature was measured daily.
Representative samples of lungs, kidneys, tonsils and spleen
ere taken at necropsy and ﬁxed in 10% buffered formalin. The
amples were then processed for parafﬁn sections and stained with
ematoxylin–eosin. 3 m-thick transverse sections were cut every
00 m from the tissues samples.
.11. Enzyme-linked immunosorbent assay (ELISA)
In mice, serum and BALF inﬂuenza-speciﬁc IgG and IgA were
easured by ELISA using methods previously described [14].
rieﬂy, 96-well microtiter plates (Nalgene Nunc, NY, USA) were
oated overnight at 4 ◦C with 1 g/ml of Fluzone®. Samples to be
ested were diluted 1:100 in PBS containing BSA 1% and incubated
or 60 min, followed by the addition of alkaline phosphatase-
onjugated goat anti-mouse IgG or anti-mouse IgA (Zymed®,
nvitrogen, USA). Color was developed with p-nitrophenyl phos-
hate disodium (Sigma® Diagnostics, Poole Dorset, UK) and optical
ensity (OD) of each well was measured at 405 nm.
In pigs, serum anti-inﬂuenza vaccine IgG and IgA antibody lev-
ls were measured. Brieﬂy, 1:50 diluted samples were assayed on
olystyrene microtitre plates coated with 100 g/ml of A/H1N1
IV: (A/swine/New Jersey/11/1976) for IgA, and 10 g/ml for IgG.
peciﬁc antibodies were detected by a horseradish peroxidase
oat anti-pig IgG or IgA conjugated (Serotec®). TMB  (3,5,5,5-
etramethylbenzidine) was used as a substrate to develop color.
D was measured at 450 nm.
.12. Hemagglutination inhibition test HIA
Hemagglutination inhibition tests were performed using
tandard protocols established in a biosafety level-3 (BSL3) labo-
atory (School of Medicine and Veterinary, UNAM, BSL3 facilities).
Since the information of the inﬂuenza strains included in
he vaccine is conﬁdential, the reference strains (A/swine/New
ersey/11/1976 (H1N1) and A/Swine/Minnesota/9088/98 (H3N2)
as employed as a source of antigen. This decision was  based
n additional data obtained in our laboratory (data not-shown)
n which a similar reactivity between the FluSure XP vaccine and
he reference strain using the same group of sera was found. In
rief, sera were heat-inactivated at 56 ◦C for 30 min and treated
ith kaolin and 5% chicken red-blood cells (RBC) overnight at
◦C. Each sample was then serially 2-fold diluted in phosphate
uffered saline (pH 7.4) and tested for HI activity against 8 hemag-
lutination (HA) units of H1N1 (A/swine/New Jersey/11/1976) and
3N2 (A/Swine/Minnesota/9088-2/98) reference strain of SIV. The
resence of HI antibody in each sample against H1 or H3 SIV
as observed by adding 0.5% chicken RBC, and incubating 20 at
5 min  at room temperature. HI antibody titer of each sample was
etermined as the reciprocal of highest dilution in which no hemag-
lutination was observed. Samples with HI activity at a dilution of
:80 were considered positive.
.13. GK-1 quantiﬁcation in M13  ﬁlamentous phageTo evaluate the expression levels of the recombinant phagemid
GK1, capillary electrophoresis gels were run in an Agilent 2100
ioanalyzer, using a Protein 80 kit. Phagemid samples were puriﬁedine 31 (2013) 4009– 4016 4011
from 2×YT by double PEG/NaCl (20%, w/v polyethylene glycol-
8000, 2.5 M NaCl) precipitation, and suspended in Tris-buffered
saline. Protein concentration was  determined by Lowry assay; a
stock solution of each sample was  prepared at 3.75 mg/ml  and
analyzed using the manufacturer’s protocol. Final protein concen-
tration in gels was 1000 ng/ml, and the relative concentration of
each protein fraction was  assessed.
2.14. Statistical analysis
Data were processed in Excel 7.0 (Microsoft, Redmond, WA,
USA). Statistical calculations were performed using the Graph-
Pad Instat software. Mean antibody levels among groups receiving
different treatments were compared by the unpaired t-test with
Welch correction. Data are also analyzed by an ANOVA and using a
Bonferroni multiple comparison test. A two-side P-value less than
0.05 were considered to indicate statistical signiﬁcance.
2.15. Ethics statement
All experiments performed in mice were approved by the ethi-
cal committee at the Instituto de Investigaciones Biomédicas, and
those performed in pigs were approved by the ethical commit-
tee at the Faculty of Veterinary Medicine, Universidad Nacional
Autónoma de México. All national guidelines on animal use were
followed, and animals were carefully handled and euthanized to
minimize suffering.
3. Results
3.1. Quantiﬁcation and antigenicity of GK-1 in FGK1
Fig. 1a shows the expression level of GK-1 in three different
batches of FGK1, produced under similar conditions. The expected
mass of cpVIII is 5.5 kDa; of GK-1 bounded to M13-cpVIII is 7.6 kDa,
and of pXI/cpVI is 12 kDa [19]. We  estimated that the major coat
protein (cpVIII) ranged from 6.1 to 6.4 kDa; FGK1 ranged from
8.3 to 9.9 kDa, and pXI/cpVI ranged from 11.4 to 12, according to
electropherogram analysis. Recombinant cpVIII-GK1 protein was
expressed in a percentage ranging from 14.8 to 23.6% of total pro-
tein, depending on the culture batch.
As data in Fig. 1b shows the antibodies induced in pigs immu-
nized with FGK1 are recognized by GK-1 in ELISA, a data compatible
with the maintaining of the epitopes in both presentations.
3.2. FGK1 more efﬁciently than synthetic GK-1 increased the level
of IgG anti-inﬂuenza antibodies
Table 1 shows the levels of anti-IgG inﬂuenza antibodies induced
by co-immunization of inﬂuenza vaccine with GK-1 recombinantly
expressed (FGK1) or synthetically produced (GK-1). As results
show higher levels of antibodies were observed when FGK1 was
employed.
3.3. Adjuvant capacity of FGK1 subcutaneously and intranasally
delivered
Table 2 shows that the subcutaneous immunization of IV plus
FGK1 signiﬁcantly increased the levels of IgG anti-inﬂuenza anti-
bodies since 60 days after immunization and until 120 days in sera
and since 45 days in BALF.
Table 3 shows a signiﬁcant increase of serum anti-inﬂuenza
IgG and IgA antibody levels in those mice immunized either
intranasally or subcutaneously with the inﬂuenza vaccine Fluzone®
along with the recombinant FGK1 at 21 and 45 days after immu-
nization. Table 3 also shows higher levels of speciﬁc BALF IgG and
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Fig. 1. (a) Percentage of recombinant PVIII in three different batches of FGK1. Different expression levels of GK-1 in M13  ﬁlamentous phage. Electropherogram shows two
higher  peaks corresponding to the cpVIII and pVI/pXI M13  proteins, and the presence of a peak representing the expression level of recombinant GK-1 in three different
batches of FGK1 (8.3–9.0 kDa) and in the M13  phage alone. (b) Levels of antibodies in sera of FGK1 immunized swine against FGK1 and GK-1 in ELISA. The obtained optical
densities indicate the maintenance of the GK-1 epitopes in FGK1.
Table 1
Effect of subcutaneous co-immunization of inﬂuenza vaccine with recombinant FGK1 or synthetic GK-1 on the level of IgG anti-inﬂuenza antibodies.
Control IV IV + GK-1 IV + FGK1 GK-1 FGK1










S† Level of IgG anti-inﬂuenza 21 days after immunization.
* Statistically different between IV + GK-1 versus IV + FGK1 using the parametric 
gA anti-inﬂuenza vaccine antibodies in mice co-immunized with
GK1. Co- immunization of mice with IV and the empty phage
M13) also induced an increase in antibody levels, although in a
on-signiﬁcant level with respect to those immunized with the
accine alone (Fig. 2)..4. Comparative effectiveness of FGK1 versus MF59 adjuvant
In order to test whether FGK1 could improve the immunogenic-
ty of the FLUAD® vaccine, which includes the MF59 adjuvant, and
able 2
erum IgG anti-inﬂuenza virus antibody levels before and after subcutaneous immunizat
Control Days after immunization Imm
Inﬂu
Sera 0.036 ± 0.07 45 0.62
0.099  ± 0.002 60 0.62
0.045  ± 0.001 90 0.88
0.003  ± 0.000 120 0.60
BALF 0.004  ± 0.01 45 0.35
0.005  ± 0.01 60 0.28
0.010  ± 0.01 90 0.50
0.005  ± 0.01 120 0.37
* Statistical different between IV versus IV + FGK1 using the parametric T-test and the oand the one-way analysis of variance and the Post Test Bonferroni.
of the adjuvant-free Fluzone® vaccine, groups of four and ﬁve mice,
respectively, were immunized with both commercial vaccines with
or without FGK1. One of the ﬁve mice belongs to those vaccinated
with Fluzone died during the bleeding. As Fig. 2 shows, increased
IgG levels were found in mice immunized with FLUAD® vaccine
with respect to those that received Fluzone®, both at 21 and 45
days after immunization. Similar increased antibody levels were
detected in those groups of mice co-immunized with FGK1 and
FLUAD® or Fluzone® at day 21 of immunization. Thus, no adju-
vant including FGK1 increases the expected levels of antibodies
at day 21. Later on (45 days after immunization), higher antibody
ion with Fluzone inﬂuenza vaccine plus FGK1.
unized with:
enza vaccine Inﬂuenza vaccine + FGK1 FGK1
 ± 0.23 0.79 ± 0.11 0.04 ± 0.002
 ± 0.22 1.10 ± 0.18* 0.01 ± 0.001
 ± 0.29 1.31 ± 0.36* 0.01 ± 0.005
 ± 0.39 1.01 ± 0.18* 0.08 ± 0.005
 ± 0.23 0.57 ± 0.23* 0.004 ± 0.01
 ± 0.12 0.51 ± 0.15* 0.003 ± 0.002
 ± 0.15 0.73 ± 0.22* 0.036 ± 0.003
 ± 0.31 0.67 ± 0.23* 0.002 ± 0.001
ne-way analysis of variance and the Post Test Bonferroni.
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Table 3
Serum and BALF anti-inﬂuenza virus antibody levels before and after subcutaneous or intranasal immunization with Fluzone inﬂuenza vaccine plus FGK1.
Route of Immunization Before Days after immunization Immunized with
Inﬂuenza vaccine Inﬂuenza vaccine + FGK1
IgG IgA IgG IgA
Subcutaneous
Serum †0.18 ± 0.1 21 1.23 ± 0.21 0.08 ± 0.01 1.90 ± 0.31* 0.03 ± 0.01
45  1.96 ± 0.6 ND 2.73 ± 0.52* ND
Intranasal
Serum 0.21  ± 0.5 21 0.32 ± 0.09 0.23 ± 0.09 0.75 ± 0.3* 0.30 ± 0.06
45  0.43 ± 0.19 0.30 ± 0.08 1.03 ± 0.29* 0.45 ± 0.08*
BALF 45 0.36 ± 0.1 0.62 ± 0.2 1.40 ± 0.48* 1.00 ± 0.1*
† Mean of the optical densities ± standard deviation.
* Statistical different between IV versus IV + FGK1 (between IgG or IgA), using the parametric T-test and the one-way analysis of variance and the Post Test Bonferroni.
Optical density levels lower than 0.2 were found in mice immunized with FGK1 only (da
separately.
Fig. 2. Levels of anti-inﬂuenza vaccine antibodies in mice immunized with Fluzone®
(adjuvant-free) or Fluad® (with MF59 adjuvant), and with or without FGK1. Individ-
ual serum levels of IgG in mice immunized with commercial anti-inﬂuenza vaccines
(FLUAD® , containing the M59  adjuvant, or FLUZONE®) with or without FGK1 or











due to FGK1 were detected in the site of injection in the vaccinated
pigs. The temperature ranges from 38.5 to 39.1 ◦C with no variationsant differences, estimated using the unpaired t-test with Welch correction, and the
ne-way analysis of variance and the Post Test Bonferroni are indicated. Results are
epresentative of two different experiments performed separately.
evels were observed in those groups co-immunized with FGK1,
isregarding the type of vaccine used.
.5. FGK1 increases antibody levels induced by inﬂuenza vaccine
n aged miceFig. 3 shows antibody levels in aged mice after intranasal immu-
ization with inﬂuenza vaccine (Istivac®), with or without FGK1
o-immunization. No increase in serum or in BALF antibodies was
etected in those mice that received only the inﬂuenza vaccine.ta not shown). Results are representative of two different experiments performed
Signiﬁcantly increased serum IgG and IgA anti-inﬂuenza and BALF
IgA antibodies were detected in those mice that received inﬂuenza
vaccine plus FGK1.
3.6. Porcine maternal anti-inﬂuenza antibodies decrease with age
In order to evaluate the effect of FGK1 on the immunogenicity
of the inﬂuenza vaccine the maternal anti-inﬂuenza antibodies in
sera of the newborn pigs was by several months after birth. Serum
maternal anti-inﬂuenza antibodies in piglets of different ages were
measured by ELISA and HIA, using H1N1 and H3N2 virus as anti-
gen sources. Sera from all 1 month-old piglets exhibited positive
haemagglutination inhibition titers to H1N1 virus from maternal
antibodies; this titer was signiﬁcantly reduced two months later
and it remained low since pigs were vaccinated (Fig. 4a). Antibody
levels below the cut-off value were detected by ELISA during the
four months except at two months of age (Fig. 4a). In contrast, no
antibodies were detected by HIA or ELISA using H3N2 virus as anti-
gen source (Fig. 4b). Four-month-old piglets were then included to
test the effect of FGK1 on elicited anti-inﬂuenza vaccine antibodies.
3.7. FGK1 increases inﬂuenza vaccine-induced antibody levels in
pigs
Fig. 5 shows antibody levels induced in pigs immunized with
one or two  doses of inﬂuenza vaccine FluSure XP®, either with or
without FGK1. No detectable antibody levels were observed 30 days
after the initial immunization. Anti-inﬂuenza vaccine antibodies
rose 15 days after the second immunization. FGK1, 15 days after
the second immunization co-administered with single or double
doses of inﬂuenza vaccine signiﬁcantly increased the expected anti-
body level in similar amounts, disregarding the number of doses
used.
The pigs co-immunized with IV in one and two  doses plus FGK
exhibited higher levels of HI than those immunized with IV alone
as soon as 30 days after immunization (Fig. 6)
3.8. Safety and tolerability of FGK1
No signs of illness or distress were noticed. No local reactionsrelated with the treatment received.
Histological examination did not reveal any differences in the
tissues inspected between those pigs immunized with inﬂuenza
vaccine with or without the presence of FGK1.
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Fig. 3. Levels of anti-inﬂuenza vaccine IgG and IgA antibodies in aged mice immunized w
anti-inﬂuenza IgG antibodies elicited in aged mice (>20 months) intranasally immunized
differences, estimated using the unpaired t-test with Welch correction and the one-way 
Fig. 4. Hemagglutination titers of maternal anti-inﬂuenza vaccine antibodies in
piglets of different ages. ELISA antibody levels (©) and hemagglutination titers ()
detected in sera from piglets of 30, 60, 90, and 120 days of age. The dashed line
and the spotted line indicate the cut-off value for ELISA and HIA, respectively, using
H1N1 (A) and H3N2 (B) as antigen sources. Sera were tested in duplicate and results
were expressed as the mean optical density, or log2 of hemagglutinaton tests. Sera
were considered positive when the obtained value is equal to or higher than cut-off
value.ith Inﬂuenza vaccine (Istivac®), with or without FGK1. Individual serum levels of
 with Istivac® inﬂuenza vaccine (IV), FGK1, or IV plus FGK1. Statistically signiﬁcant
analysis of variance and the Post Test Bonferroni are indicated.
4. Discussion
Adjuvants play an important role in current vaccine devel-
opment, modulating the speciﬁc antigen recognition through
effective immune cell recruitment that promotes their activation,
and the production of the appropriate cytokines. We previously
reported the effectiveness of a new adjuvant, a synthetically pro-
duced 18-aa peptide named GK-1, to improve the protective effect
induced by inﬂuenza vaccine in a murine model.
In this study, we  are reporting a novel presentation of GK-1,
recombinantly expressed on the pVIII surface protein of a bacterio-
phage. This new GK-1 presentation (FGK1) also exhibited effective
adjuvant properties. FGK1 co-immunized with IV subcutaneously
administered increased the expected sera antibodies as shown in
different independent experiments (Table 1 and Fig. 2). Increased
levels of antibodies were obtained when FGK1 was  employed with
the inﬂuenza vaccine disregarding difference between the anti-
body levels induced by the vaccine itself. Moreover, intranasal
co-immunization of IV plus FGK1 effectively increased the expected
serum and BALF IgG and IgA speciﬁc antibody levels respect to
those induced by the vaccine alone. It is particularly relevant to
test the effect of an adjuvant in the speciﬁc antibody levels since a
clear correlation between their levels and the protection induced
has been extensively reported [21] Those levels exceeded also the
effect induced by the recently licensed adjuvant-containing version
of human inﬂuenza vaccine. Notably, FGK1 improved the antibody
response induced when the vaccine was intranasally administered.
The latter is a ﬁnding of particular relevance, since this is the route
of entrance of inﬂuenza virus and where the virus would encounter
a local increased speciﬁc immunity which could more effectively
control the infection. Compared with the oil-in-water adjuvant
MF59, FGK1 showed a good potential as an adjuvant. In this study
we proved that GK-1, expressed in recombinant form with M13
phage, preserve its immunogenic properties. This ﬁnding is of spe-
cial relevance since FGK1 could be massively produced without
signiﬁcantly increasing the price of the inﬂuenza vaccine itself.
The effectiveness of FGK1 to elicit anti-inﬂuence antibodies
in pigs reported in this study, along with its low cost, let us
propose this new adjuvant to be included in effective control
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Fig. 5. Levels of anti-inﬂuenza vaccine antibodies in pigs immunized with inﬂuenza vacci ®
subcutaneously immunized with single or double doses of commercial vaccine (FluSure X
using  the unpaired t-test with Welch correction, are indicated.
Fig. 6. Hemagglutination titers in sera of pigs immunized with IV with or without
co-immunization with FGK1 Hemagglutination titers detected in sera 30 and 45 days















fntigen sources. Sera were tested in duplicate and results were expressed as log2
f hemagglutinaton tests. Sera were considered positive when the obtained value is
qual to or higher than cut-off value.
rograms designed to reduce inﬂuenza virus transmission in pig
arms, an intervention essential to prevent the eventual transmis-
ion of new virus strains to humans (http://www.cidrap.umn.edu/
idrap/content/inﬂuenza/general/news/dec0211vaccine-jw.html).
It is worthy to mention some recent ﬁndings that start to reveal
he possible mechanisms underlying the adjuvant properties of GK-
. GK-1 exerts a direct “adjuvant-like” effect on DC cells that leads
o up-regulation of co-stimulatory molecules and enhanced T cell
ctivation, both in vitro and in vivo. Additionally, LPS plus GK-1
how a synergistic effect in the induction of T cell proliferation
nd, even more strikingly, in the induction of pro-inﬂammatory
ytokines [6]. In spite of these capacities, GK-1 did not promote the
ormation of granuloma in mice and pigs, neither in its synthetic [8],ne (Flusure , Pﬁzer, USA), with or without FGK1. Individual serum IgG levels in pigs
P®) with or without FGK1. Statistically signiﬁcant differences at P < 0.05, estimated
nor in its recombinant presentation as shown herein. Moreover, no
signs of discomfort or pathology were detected in pigs immunized
with the inﬂuenza vaccine plus FGK1, information that support the
potential interest of FGK1 to be included in the inﬂuenza vaccine
formulation.
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